Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) Starts Presentation at LD Micro Main Event
Peregrine Pharmaceuticals (NASDAQ:PPHM) is a company transitioning from an R&D focused business to a pure play contract development and manufacturing organization (CDMO). Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. The company is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers. For more information, visit the company’s website at www.peregrineinc.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access…







